Cardiovascular Drugs Practice Questions

Q: Which of the following statements best describes long-acting nitrate preparations?

Tolerance often develops. **Explanation:** **1. Why Option A is Correct:** Nitrate tolerance (tachyphylaxis) is a well-documented phenomenon where the clinical efficacy of the drug diminishes significantly with continuous exposure. The underlying mechanism involves the **depletion of free sulfhydryl (-SH) groups** (required to convert nitrates to Nitric Oxide) and increased production of free radicals (oxidative stress) that inhibit guanylyl cyclase. To prevent this, a **"nitrate-free interval"** of 8–12 hours (usually at night) is mandatory for long-acting preparations like isosorbide mononitrate or transdermal patches. **2. Why Other Options are Incorrect:** * **Option B:** Nitrates act directly on vascular smooth muscle to cause vasodilation. Their mechanism is independent of beta-receptors; therefore, beta-blockers do not inhibit their effect. In fact, they are often used together to prevent reflex tachycardia. * **Option C:** Sublingual nitrates cause a rapid, high-peak plasma concentration, which is **more** likely to cause immediate "nitrate headaches" compared to the slow, sustained release of transdermal patches. * **Option D:** Oral nitrates undergo extensive **first-pass metabolism** in the liver, making them significantly less potent and slower-acting than sublingual preparations, which bypass the liver and enter the systemic circulation directly. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Sublingual Nitroglycerin (GTN) is the drug of choice for acute anginal attacks. * **Storage:** GTN is volatile and light-sensitive; it should be stored in dark glass bottles. * **Contraindication:** Never co-administer nitrates with **Sildenafil** (PDE-5 inhibitors) as it can lead to life-threatening hypotension. * **Side Effects:** Throbbing headache (most common), postural hypotension, and reflex tachycardia.

Q: Esmolol is a short-acting beta-blocker because:

Its plasma hydrolysis by esterases is rapid.. **Explanation:** **Why the correct answer is right:** Esmolol is a unique, ultra-short-acting cardioselective $\beta_1$ antagonist. Its rapid onset and extremely short duration of action (half-life of approximately **9 minutes**) are due to its chemical structure, which contains an **ester linkage**. This linkage is rapidly hydrolyzed by **red blood cell (RBC) esterases** (not plasma cholinesterase) into an inactive metabolite. Because these esterases are ubiquitous and highly efficient, the drug is cleared from the systemic circulation almost immediately once the infusion is stopped. **Analysis of incorrect options:** * **Option A:** High plasma protein binding generally prolongs a drug's half-life by protecting it from metabolism and excretion. Esmolol has moderate protein binding (~55%), which does not account for its short duration. * **Option C:** High lipid solubility (like Propranolol) allows drugs to cross the blood-brain barrier and undergo extensive hepatic metabolism, but it typically leads to a longer half-life and larger volume of distribution, not ultra-short action. * **Option D:** Esmolol has very low oral bioavailability and is administered exclusively via **intravenous infusion**. High oral bioavailability is irrelevant to its rapid clearance. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Ideal for emergency situations requiring "minute-to-minute" control, such as **aortic dissection**, intraoperative hypertension, and supraventricular arrhythmias (AFib/Aflutter). * **Safety:** If side effects like bradycardia or hypotension occur, they resolve within 10–20 minutes of stopping the infusion. * **Metabolism:** It is metabolized by **RBC esterases**, making it safe to use in patients with liver or kidney dysfunction.

Q: Which of the following is NOT a potassium channel opener?

Amiodarone. **Explanation:** The correct answer is **Amiodarone** because it is a **Class III antiarrhythmic agent** that primarily acts as a **potassium channel blocker**, not an opener. By blocking outward $K^+$ channels, it prolongs the action potential duration and the effective refractory period, which is the hallmark of its antiarrhythmic effect. **Why the other options are Potassium Channel Openers:** Potassium channel openers work by activating ATP-sensitive $K^+$ channels ($K_{ATP}$), leading to $K^+$ efflux, membrane hyperpolarization, and subsequent closure of voltage-gated calcium channels. This results in smooth muscle relaxation. * **Pinacidil:** A potent vasodilator used historically for hypertension; it acts directly on vascular smooth muscle. * **Diazoxide:** Used intravenously for hypertensive emergencies and orally to treat hyperinsulinemic hypoglycemia (as it inhibits insulin release by opening $K_{ATP}$ channels in pancreatic beta cells). * **Nicorandil:** A unique "dual-action" drug used in angina. It acts as both a $K_{ATP}$ channel opener and a nitrate-like nitric oxide donor, providing both arterial and venous dilation. **High-Yield Clinical Pearls for NEET-PG:** * **Minoxidil** is another important $K_{ATP}$ opener used for refractory hypertension and androgenic alopecia (side effect: hypertrichosis). * **Amiodarone** is "broad-spectrum"; while classified as Class III, it also exhibits Class I, II, and IV activities. * **Side Effects of Amiodarone:** Pulmonary fibrosis, thyroid dysfunction (due to high iodine content), corneal microdeposits, and blue-gray skin discoloration.

Q: Which of the following drugs can cause Torsades de pointes?

Quinidine. **Explanation:** **Torsades de Pointes (TdP)** is a specific type of polymorphic ventricular tachycardia associated with a **prolonged QT interval**. **1. Why Quinidine is correct:** Quinidine is a **Class IA antiarrhythmic**. Its primary mechanism involves blocking fast sodium channels, but it also significantly blocks **potassium channels** (delayed rectifier current, $I_{Kr}$). By inhibiting potassium efflux during repolarization, it prolongs the action potential duration (APD) and the QT interval. This creates a window for "early after-depolarizations" (EADs), which trigger TdP. This phenomenon is often referred to as "Quinidine Syncope." **2. Why the other options are incorrect:** * **Lignocaine (Class IB):** These drugs have the shortest dissociation kinetics and actually **shorten** the action potential duration. They do not cause QT prolongation and are therefore not associated with TdP. * **Esmolol (Class II):** As a cardioselective beta-blocker, it decreases SA and AV node conduction. It does not significantly affect the ventricular repolarization phase or the QT interval. * **Flecainide (Class IC):** These are potent sodium channel blockers that significantly prolong the QRS duration (conduction slowing) but have **minimal effect** on the QT interval. Their main risk is "re-entrant" ventricular tachycardia, especially post-MI. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for TdP-causing drugs (ABCDE):** **A**ntiarrhythmics (Class IA & III), **B**e-blockers (Sotalol - exception), **C**ytochrome P450 inhibitors, **D**iuretics (via hypokalemia), **E**rythromycin (Macrolides/Fluoroquinolones/Antipsychotics). * **Class III drugs** (e.g., Sotalol, Dofetilide) have the highest risk of TdP, but **Amiodarone** (despite prolonging QT) rarely causes TdP due to its homogenous effect on ventricular repolarization. * **Treatment of choice** for drug-induced Torsades de pointes is **Intravenous Magnesium Sulfate**.

Q: All are toxicities seen with amiodarone therapy except?

Productive cough. Amiodarone is a Class III antiarrhythmic drug known for its long half-life and extensive side-effect profile due to its high iodine content and tendency to accumulate in various tissues. **Why "Productive Cough" is the correct answer:** Amiodarone is notorious for causing **Pulmonary Toxicity**, most commonly presenting as **interstitial lung disease or pulmonary fibrosis**. This typically manifests as a **dry, non-productive cough** and progressive dyspnea. A productive cough is not a characteristic feature of amiodarone-induced lung injury and usually suggests an infectious process. **Analysis of Incorrect Options:** * **Pulmonary Fibrosis:** This is the most serious side effect. It is dose-dependent and results from direct toxicity and an inflammatory response leading to alveolar damage. * **Corneal Microdeposits:** These occur in nearly all patients treated for more than six months. They are usually asymptomatic and do not require discontinuation of the drug, though they can occasionally cause "halo vision." * **Cirrhosis of Liver:** Amiodarone is metabolized in the liver and can cause elevated transaminases. Long-term use can lead to steatohepatitis and, rarely, cirrhosis. **NEET-PG High-Yield Pearls:** * **Thyroid Dysfunction:** Amiodarone can cause both **hypothyroidism** (Wolff-Chaikoff effect) and **hyperthyroidism** (Jod-Basedow phenomenon) due to its 37% iodine content. * **Skin:** Can cause a distinctive **blue-gray skin discoloration** (photodermatitis). * **Monitoring:** Baseline and periodic Chest X-rays, Pulmonary Function Tests (PFTs), Liver Function Tests (LFTs), and Thyroid Function Tests (TFTs) are mandatory for patients on chronic therapy.

Q: Which of the following is not an adverse effect of amiodarone?

Nephrotoxicity. **Explanation:** Amiodarone is a Class III antiarrhythmic drug known for its high iodine content and exceptionally long half-life (several weeks). It is notorious for causing multi-organ toxicities due to its accumulation in various tissues; however, **nephrotoxicity is not a recognized adverse effect** of the drug. **Why Nephrotoxicity is the correct answer:** Amiodarone is primarily metabolized by the liver (CYP3A4) and excreted via the biliary tract. Unlike many other cardiovascular drugs, it does not require dose adjustment in renal failure and does not cause direct structural or functional damage to the kidneys. **Analysis of incorrect options:** * **Hyperthyroidism (and Hypothyroidism):** Amiodarone is 37% iodine by weight. It can cause hypothyroidism (Wolff-Chaikoff effect) or hyperthyroidism (Jod-Basedow phenomenon). * **Corneal microdeposits:** These occur in nearly all patients on long-term therapy. They are usually asymptomatic and do not require drug discontinuation, though they can cause "halos" around lights. * **Pulmonary fibrosis:** This is the most serious/lethal side effect. It is dose-dependent and results from chronic interstitial pneumonitis. **High-Yield Clinical Pearls for NEET-PG:** * **Skin:** Can cause a distinctive **blue-gray skin discoloration** (Photosensitivity). * **Liver:** Can lead to elevated transaminases and cirrhosis. * **Monitoring:** Baseline and periodic **Chest X-ray, PFTs, LFTs, and Thyroid Function Tests (TFTs)** are mandatory. * **Mechanism:** While Class III (K+ channel blocker), it exhibits properties of all four Vaughan-Williams classes.

Q: Which of the following drugs are implicated in the development of heart block?

All the above. Heart block occurs when there is a delay or interruption in the conduction of electrical impulses from the atria to the ventricles. This can be induced by drugs that depress the **Sinoatrial (SA) node** or the **Atrioventricular (AV) node**. **Explanation of Options:** * **Beta-blockers (Option A):** These drugs act as negative dromotropes by blocking $\beta_1$ receptors in the heart. This decreases the rate of conduction through the AV node and increases the refractory period, which can lead to various degrees of heart block, especially in patients with pre-existing conduction defects. * **Lithium (Option B):** While primarily used as a mood stabilizer, Lithium is known for its cardiac side effects. It can interfere with sinus node function (causing Sick Sinus Syndrome) and impair AV conduction, leading to bradycardia and heart block. * **Adenosine (Option C):** This drug is the treatment of choice for PSVT. It works by activating $A_1$ receptors, which increases $K^+$ efflux and inhibits $Ca^{2+}$ current. This causes a transient but potent suppression of the AV node, which can manifest as a temporary high-grade heart block. **Conclusion:** Since all three drugs can impair cardiac conduction, **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** 1. **Other drugs causing heart block:** Non-dihydropyridine Calcium Channel Blockers (Verapamil, Diltiazem), Digoxin, and Amiodarone. 2. **Digoxin Toxicity:** Classically causes heart block with increased atrial rate (Atrial Tachycardia with AV block). 3. **Management:** Atropine is the initial drug of choice for symptomatic bradycardia/heart block, but it is ineffective in high-grade blocks (Mobitz II or 3rd degree), where a pacemaker is required.

Q: Which of the following antihypertensive drugs has a central sympatholytic action?

alpha-methyl dopa. **Explanation:** **Alpha-methyl dopa** is the correct answer because it is a classic **centrally acting sympatholytic** agent. It acts as a prodrug that is converted into alpha-methyl norepinephrine in the brain. This metabolite acts as a potent agonist at **presynaptic alpha-2 (α2) adrenergic receptors** in the vasomotor center of the medulla. Stimulation of these receptors inhibits the outflow of sympathetic impulses to the heart and peripheral vasculature, leading to a decrease in peripheral vascular resistance and blood pressure. **Analysis of Incorrect Options:** * **Levodopa:** A precursor of dopamine used in Parkinson’s disease. While it crosses the blood-brain barrier, its primary role is to replenish dopamine levels in the basal ganglia, not to lower blood pressure via sympatholysis. * **Carbidopa:** A peripheral dopa-decarboxylase inhibitor. It does not cross the blood-brain barrier and is co-administered with levodopa to prevent its peripheral conversion to dopamine, thereby reducing systemic side effects. * **Hydralazine:** A **direct-acting peripheral vasodilator** that relaxes arteriolar smooth muscle. It does not have a central mechanism of action and often causes reflex tachycardia. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Alpha-methyl dopa remains a preferred drug for managing **hypertension in pregnancy** (along with Labetalol and Nifedipine). * **Side Effects:** A key adverse effect is a **positive Coomb’s test**, which can rarely lead to autoimmune hemolytic anemia. It can also cause sedation and hyperprolactinemia. * **Other Central Sympatholytics:** Clonidine (α2 agonist) and Moxonidine (Imidazoline receptor agonist) are other drugs in this class.

Question 1

Which of the following statements best describes long-acting nitrate preparations?

Accepted Answer

Tolerance often develops

Answer

Their effect can be blocked by high doses of beta-selective inhibitors

Answer

Transdermal patches are more likely to be associated with headaches than are sublingual nitrates

Answer

Oral preparations are more effective than sublingual ones

Question 2

Esmolol is a short-acting beta-blocker because:

Accepted Answer

Its plasma hydrolysis by esterases is rapid.

Answer

It has more plasma protein binding.

Answer

It has high lipid solubility.

Answer

It has high oral bioavailability.

Question 3

Which of the following is NOT a potassium channel opener?

Accepted Answer

Amiodarone

Answer

Pinacidil

Answer

Diazoxide

Answer

Nicorandil

Question 4

Which of the following drugs can cause Torsades de pointes?

Accepted Answer

Quinidine

Answer

Lignocaine

Answer

Esmolol

Answer

Flecainide

Question 5

Which of the following statements best explains the action of nitroglycerine on coronary vessels?

Accepted Answer

It preferentially dilates conducting arteries without affecting resistance arterioles.

Answer

It mitigates angina pectoris by increasing total coronary flow.

Answer

It preferentially dilates autoregulatory arterioles without affecting the larger arteries.

Answer

It mainly decreases the afterload.

Question 6

What is the primary rationale for co-administering nifedipine and a beta-blocker?

Accepted Answer

To counteract the increased sympathetic activity induced by nifedipine

Answer

To decrease pedal edema caused by nifedipine

Answer

For the anti-congestive heart failure action of propranolol

Answer

To achieve the antiarrhythmic effect of nifedipine

Question 7

All are toxicities seen with amiodarone therapy except?

Accepted Answer

Productive cough

Answer

Pulmonary fibrosis

Answer

Corneal microdeposits

Answer

Cirrhosis of liver

Question 8

Which of the following is not an adverse effect of amiodarone?

Accepted Answer

Nephrotoxicity

Answer

Hyperthyroidism

Answer

Corneal microdeposits

Answer

Pulmonary fibrosis

Question 9

Which of the following drugs are implicated in the development of heart block?

Accepted Answer

All the above

Answer

Beta blockers

Answer

Lithium

Answer

Adenosine

Question 10

Which of the following antihypertensive drugs has a central sympatholytic action?

Accepted Answer

alpha-methyl dopa

Answer

levodopa

Answer

carbidopa

Answer

hydralazine

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?